Day-one subcutaneous Leqembi lets eligible people with early Alzheimer's start treatment at home with weekly injections instead of clinic infusions. What did not change in 2026 is who qualifies, how much slowing to expect, and the need for brain-safety monitoring.
Leqembi is an anti-amyloid drug that removes amyloid plaques linked to Alzheimer's. Early Alzheimer's here means mild cognitive impairment or mild dementia due to Alzheimer's with confirmed amyloid buildup. The Alzheimer's Association reported FDA approval on July 13, 2026 for weekly Leqembi Iqlik shots as starting therapy in the Alzheimer's Association announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How is starting treatment different now
- Who can consider this start
- How well does it work
- What safety monitoring stays in place
- What to ask about cost and next steps
How is starting treatment different now
Before July 2026, every patient had to start with biweekly IV infusions in a clinic. An Eisai/Biogen update says an August 26, 2025 approval allowed weekly 360-mg Leqembi Iqlik only for maintenance after 18 months of IV treatment. The new initiation regimen is 500 mg weekly given as two 250-mg autoinjector injections of about 15 seconds each.
Drug Topics reports the shots can be given at home by the patient or a caregiver, replacing required starter infusions in the Drug Topics report. Eisai announced the initiation autoinjector became commercially available in the United States on Aug. 24, 2026.
Who can consider this start
Eligibility did not change with the new starter. The treatment is for adults with mild cognitive impairment or mild dementia due to Alzheimer's who have confirmed amyloid buildup.
That is the same early-Alzheimer's population studied in the IV Clarity AD trials, as described by Drug Topics. For families, this means the first question is still diagnosis, not delivery method. A doctor must confirm the stage and test for amyloid before home shots are an option.
- Mild cognitive impairment due to Alzheimer's
- Mild dementia due to Alzheimer's
- Confirmed amyloid pathology
How well does it work
Expectation still rests on IV lecanemab trials. Those trials showed about 0.45-point less decline on CDR-SB at 18 months along with amyloid reduction, as reported by Drug Topics.
Subcutaneous starting doses relied on matching drug levels and similar plaque removal, not a new trial measuring memory outcomes. In practical terms, the record supports slower decline on average rather than restored memory. Families weighing home starts should judge convenience separately from strength of benefit.
What safety monitoring stays in place
Safety follow-up did not change, as Practical Neurology reported in its summary of the FDA approval in the Practical Neurology report. Patients still need MRI checks for ARIA, APOE ε4 gene testing for higher ARIA risk, and caution with blood thinners because of brain-bleed risk.
Home injections add local site reactions to watch for, not fewer brain-safety steps. Ask the clinic to schedule MRIs, review gene-test results, and review blood-thinner use before the first shot. Report new symptoms promptly and ask how injection-site soreness should be handled.
- MRI plan for ARIA
- APOE ε4 result on file
- Anticoagulant review
- Injection-site check
What to ask about cost and next steps
Drug Topics lists traditional IV Leqembi at a $26,500 annual list price with Medicare Part B coverage tied to CMS-registry enrollment in the Drug Topics report. That price and registry path describe IV care.
Confirm current terms for the home starter with the clinic and drug plan. Bring a full drug list, insurance card, and APOE result to that visit.
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: What People With Mild Cognitive Impairment Should Know About the News
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What People With Mild Cognitive Impairment Should Know About the News
- Why the AAIC 2026 Soccer Study Does Not Prove Dementia: What Researchers Still Need to Learn for Adults With Memory Concerns
